Touchlight’s cell-free, enzymatic dbDNA manufacturing platform underpins the NEOVACC Phase I trial led...
Read More
Touchlight is proud to announce a strategic partnership with SVF Vaccines to progress SVF’s innovative Hepatitis B/D vaccine into clinical development.
Read More
Touchlight and New England Biolabs launch the EnClose™ Cell‑free dbDNA™ Synthesis Kit, enabling rapid, scalable, cell‑free production of high‑purity DNA for next‑generation mRNA, gene therapy, and vector development.
Read More
Touchlight today announced the expansion of its groundbreaking mbDNA™ platform with the introduction of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA.
Read More
Touchlight announced today that its proprietary z- dbDNA™ technology is to be utilised as a critical starting material in the manufacture of a cutting-edge gene therapy for a US-based clinical…
Read More
Touchlight, a pioneering leader in DNA manufacturing technologies, has been named the 2025 FOYA Category Winner for Innovation in the International Society for Pharmaceutical Engineering (ISPE) Facility of the Year…
Read More
Touchlight Introduces mbDNA™: A “best-in-class" circular single stranded DNA (ssDNA) platform enabling superior gene editing Published: 30 July 2025Touchlight, a pioneer in cell-free DNA innovation, is proud to announce the…
Read More
Touchlight Wins ISPE Facility of the Year Award for Innovation, Recognised for Revolutionary dbDNA™ Manufacturing at Morelands Facility Published: 12 May 2025Touchlight, a pioneering leader in synthetic DNA technology, is…
Read More
